Technical whitepaper developed with Agilent Technologies. Companion to our JMD QC Framework publication and Agilent webinar on end-to-end QC processes for RNA biomarker discovery. Watch the webinar here.
Summary: Decode Health has built a mature AI/ML platform to accelerate clinical decision-making and population health analytics solutions. Check out the article below to learn more about recent collaborative efforts with a global pharmaceutical company and leading technology firm to better detect disease and identify patients at risk of high-cost events using predictive approaches in oncology and autoimmune disease.
Two-year Small Business Innovation Research (SBIR) award strengthens the company’s mission to transform complex biomedical data into real-world solutions; the project will develop a blood-based, AI-driven readout of MS disease biology with Broad Clinical Labs, the Accelerated Cure Project for MS, and a broad network of industry and academic collaborators.
Nashville gets a lot of attention for its successes — the cranes dotting the skyline, the big businesses moving to town. But the city is also facing significant challenges. Housing, a good education and a good wage are out of reach for too many Nashvillians. It’s up to those on our 2024 In Charge list to push the city toward a brighter future.
At Decode Health, we empower the healthcare industry to implement and leverage artificial intelligence (AI) approaches, including machine learning, across a wide range of clinical applications. Data quality is paramount, especially when utilizing large, disparate datasets to address complex diseases. Decode has developed a platform that ensures the precision and reproducibility of insights and results from diverse data sources. The platform features a robust quality control (QC) framework that optimizes the efficiency and accuracy of biomarker discovery. Check out the article below to learn how our technology accelerates the biomarker discovery R&D process, widens the impact of personalized medicine, and unlocks new insights to fuel better ways to diagnose and treat patients.
Current methods of managing healthcare are unsustainable, with chronic disease treatment alone putting a $4 trillion annual strain on the U.S. economy. Healthcare professionals across the board agree that earlier diagnosis, better preventative care, and improved disease management will significantly reduce those costs while improving the lives of millions of Americans. In a healthcare landscape rapidly moving towards personalized patient care, precision medicine offers a unique solution.
Senior digital health and health IT leaders from across the U.S. will convene in Nashville, March 26-29, for ViVE 2023. This year, Decode Health is sponsoring the event as part of the Friends of Project Healthcare Pavilion.
Decode Health was recently honored for its commitment to advancing precision medicine and extraordinary promise for future endeavors with a 2022 Nashville Entrepreneur Center NEXT Award for healthcare innovation.
Decode Health today announced it received a $248,000 one year grant from the National Institutes of Health (NIH) to create new methods to distinguish relapsing-remitting and progressive forms of multiple sclerosis (MS).
In the U.S., the cost of chronic diseases is more than $3.7T1 annually. Massive amounts of healthcare data are generated through wearable data, healthcare claims, electronic health records, and even complex genomic datasets. By 2025, the average individual will accumulate more than 4,900 daily digital device interactions2. Data alone, however, isn't the answer. The key is to find patterns within the data to proactively intervene and reduce the inefficiency within the $808 billion3 healthcare industry.
Precision medicine R&D platform
© DECODE HEALTH. ALL RIGHTS RESERVED | PRIVACY POLICY | FCOI Policy